0
0

Hatch-Waxman Improvement Act of 2022

12/29/2022, 5:33 PM

Congressional Summary of S 4378

Hatch-Waxman Improvement Act of 2022

This bill extends through FY2026 provisions that establish a period of market exclusivity for certain new drugs with single enantiomers (i.e., one of a pair of molecules that are mirror images of one another).

Current Status of Bill S 4378

Bill S 4378 is currently in the status of Bill Introduced since June 13, 2022. Bill S 4378 was introduced during Congress 117 and was introduced to the Senate on June 13, 2022.  Bill S 4378's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. as of June 13, 2022

Bipartisan Support of Bill S 4378

Total Number of Sponsors
1
Democrat Sponsors
0
Republican Sponsors
1
Unaffiliated Sponsors
0
Total Number of Cosponsors
0
Democrat Cosponsors
0
Republican Cosponsors
0
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill S 4378

Primary Policy Focus

Health

Alternate Title(s) of Bill S 4378

Hatch-Waxman Improvement Act of 2022
Hatch-Waxman Improvement Act of 2022
A bill to reauthorize a provision of the Federal Food, Drug, and Cosmetic Act pertaining to drugs containing single enantiomers.

Comments